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Background: Hyperglycemia increases the risk of gastric cancer in H. pylori-infected patients. High glucose could
increase endothelial permeability and cancer-associated signaling. These suggest high glucose may affect H. pylori
or its infected status.
We used two strains to investigate whether H. pylori growth, viability, adhesion and CagA-phosphorylation level in
the infected-AGS cells were influenced by glucose concentration (100, 150, and 200 mg/dL).
Results: The growth curves of both strains in 200 mg/dL of glucose were maintained at the highest optimal
density after 48 h and the best viability of both strains were retained in the same glucose condition at 72 h.
Furthermore, adhesion enhancement of H. pylori was significantly higher in 200 mg/dL of glucose as compared to
that in 100 and 150 mg/dL (p < 0.05). CagA protein also increased in higher glucose condition. The cell-associated
CagA and phosphorylated-CagA was significantly increased in 150 and 200 mg/dL of glucose concentrations as
compared to that of 100 mg/dL (p < 0.05), which were found to be dose-dependent.
Conclusion: Higher glucose could maintain H. pylori growth and viability after 48 h. H. pylori adhesion and CagA
increased to further facilitate the enhancement of cell-associated CagA and phosphorylated CagA in higher
glucose conditions.
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Helicobacter pylori infection in the human stomach causes
chronic inflammation, leading to peptic ulcers and gastric
malignancy [1-3]. Other cofactors may be involved in the
H. pylori related gastric carcinogenesis, because not all
H. pylori-infected patients develop gastric cancer. Some
reports have shown that there is a significantly higher
prevalence of H. pylori infection in patients with type 2
diabetes mellitus (DM), who also have a lower eradication
rate [4-6]. In particular, a higher fasting plasma glucose
level in H. pylori-seropositive patients may correlate with
an increased risk of gastric cancer up to a nearly 3.5-4.2
fold increase [7]. These data suggest that hyperglycemia* Correspondence: sheubs@mail.ncku.edu.tw
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unless otherwise stated.may be an important cofactor to influence H. pylori
mediated gastric carcinogenesis [8].
To establish H. pylori colonization and chronic inflam-
mation at the gastric epithelium, adherence can serve as
the first step of infection and then deliver effectors to
induce inflammation [9-11]. The major adhesion, blood
group antigen binding adhesin (BabA), binds to Lewis
b (Leb) and related ABO antigens to initiate bacterial
adhesion and stimulate IL-8 secretion [12-14]. More-
over, cytotoxin-associated gene A antigen (CagA), an
onco-protein, is translocated into gastric epithelial cell
through type IV secretion system of H. pylori [15-18].
The tyrosine in the EPIYA motif of CagA C-terminal
could be phosphorylated [19] and thus can change the
cell morphology, increase cell motility, and promote
cell proliferation [20-23].
Hyperglycemia leads into an increased risk of gastric
cancer in the H. pylori-infected patients [7]. Moreover,
high glucose can enhance cancer-associated Wnt/β-d. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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hyperglycemia, H. pylori and gastric cancer. High glucose
could also increase endothelial permeability and altered
basement membrane composition and structure [25,26],
which may make H. pylori infection occur in a high glucose
condition, such as the patients with hyperglycemia. There-
fore, it is worth investigating whether or not glucose can
influence the expressions of H. pylori virulence to promote
carcinogenesis. This study is original to illustrate that
higher glucose concentrations can promote bacterial
growth of H. pylori isolates, facilitate bacterial adhesion
to gastric epithelial cells, and up-regulate the expression
of CagA protein to facilitate more virulence related to type
IV secretion system.
Methods
Assessment to the H. pylori growth under different
glucose levels
Strain J99 and ATCC 43504 were purchased from ATCC
and stored at –70°C in BHI with 30% glycerol until testing
was conducted. H. pylori strains were cultured on CDC
anaerobic blood agar (BBL, Microbiology Systems, Cock-
eysville, MD, USA). When determining growth curve, H.
pylori strains were cultured in Brucella broth containing
10% horse serum and different concentration of glucose
(100, 150, 200 mg/dL) at 37°C for 3 days in a microaero-
philic conditions, with shaking at 50-52 rpm. The optical
density (OD) at 600 nm of bacterial growth was evaluated
at 20, 48, and 72 h. Bacterial viability was detected at 48
and 72 h of growth curve and analyzed by serious dilution
to count colony formation unit (CFU) per ml.
Co-culture of H. pylori & AGS cells under different
glucose levels
The human gastric adenocarcinoma cell line, AGS, was
purchased from Food Industry Research and Development
Institute in Taiwan and was grown in the cell medium,
Ham’s F-12 medium (GIBCO BRL, Grand Island, NY)
containing 10% FCS. The cells were sub-cultured every
second to third day. To conduct the H. pylori adhesion
assays in AGS cells, the AGS cells (5.5 × 105/well) were
seeded to one well of 6-well plates for 22 h and then
replaced the cell medium to cell medium supplemented
with different concentrations (100, 150, 200 mg/dL) of
glucose for 3.5-4 h. After washing with the mixture of
F-12 medium and 1× PBS (1:1) to the AGS cells cultivated
in medium with specific concentrations of glucose, the
serum-free F-12 medium (SFM) with the same glucose
concentration were added again. As well, the both H.
pylori strain J99 and 43504 were cultured for 20 hours in
Brucella broth including 10% horse serum under three
glucose concentrations, including 100, 150, 200 mg/dL,
respectively. The bacteria shall be washed twice with the
SFM containing the same glucose contraction beforeadding to cells. After washing, these bacterial suspensions
in the SFM will be then applying to the well that con-
tained AGS cells with the same concentration of glucose
treatment at Multiplicity of infection (MOI) as 30-40. In
each glucose level, there should be co-cultured with
H. pylori and AGS cells for two wells, including the
first one for adhesion assay, the second one for the
detection of CagA phosphorylation. The first well was
washed three times with the SFM 30 min later to detect
bacterial adhesion and the second well was incubated for
4 h to detect CagA phosphorylation.
H. pylori adhesion assay to AGS cells under different
glucose levels
In order to calculate the percentage of bacterial adhesion,
lysate of H. pylori adhering to AGS cells and the original
suspension of H. pylori adding to adhesion assays were
seriously diluted respectively and grown on CDC plates to
count bacterial CFU. The adhesion CFU divided by the
original CFU is the adhesion percentage of H. pylori.
Western blotting for detection H. pylori BabA, CagA and
CagA phosphorylation
The bacterial suspension adding to detect adhesion ability
under different glucose concentration was also collected
to determine protein concentration. An equal amount of
bacterial protein (1.5-2 μg) was used to detect the expres-
sion of BabA and CagA by performing western blotting.
Moreover, the well of co-cultured H. pylori and AGS
cells incubated for 4 h was washed 3 times to collect
cell lysates for detection of CagA and CagA phosphor-
ylation. Antibodies (Ab) used in western blotting included
the anti-BabA as applied in our previous report [27],
anti-phospho-tyrosine (PY99) (Santa Cruz Biotechnology),
anti-CagA (Santa Cruz Biotechnology) and anti-beta Actin
(Minipore) Abs.
Statistics
The statistical analysis was performed by using a paired
t test. The differences were considered to be significant
at p < 0.05.
Results
Effect of glucose level on H. pylori growth curve
and viability
Strain J99 and 43504, grown in broth containing three
concentrations of glucose (100, 150, 200 mg/dL), were
applied to detect the growth curve during 72 h (Figure 1A
and B). Optical density of strain J99 at 200 mg/dL were
kept on increasing at 72 h, however, OD value was
decreased in 100 and 150 mg/dL of glucose conditions
at the same time (Figure 1A). The significant difference
between 3 growth curves of strain J99 was observed at
48 h (J99-100 vs. J99-150, p < 0.05; J99-100 vs. J99-200,
Figure 1 H. pylori growth and viability was increased under higher glucose level after 48 hr. (A, B) Strain J99 and 43504 grew in Brucella
broth containing 10% horse serum and different level of glucose (100, 150, 200 mg/dL). The optical density (OD) at 600 nm of bacterial growth was
evaluated during 72 h. (C, D) Colony formation unit (CFU) of strain J99 and 43504 was determined at growth curve of 48 and 72 h. * indicated
p < 0.05 (paired t test).
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vs. J99-150, p = 0.05; J99-100 vs. J99-200, p < 0.05; J99-150
vs. J99-200, p < 0.05). Growth of strain 43504 in higher
glucose concentrations (150 and 200 mg/dL) had the
trend of higher optimal density, as compared to low
glucose (100 mg/dL), except 48 h. Besides strain 43504
at 48 h, H. pylori viability was increased by the increasing
glucose concentration (Figure 1C and D). Especially at
72 h, the viability of two strains cultured in 150 and
200 mg/dL were consistently increased as compared to
that in 100 mg/dL (p < 0.05). Viability showed 3-4 fold
increases in 200 mg/dL as compared to that in 150 mg/dL
(p < 0.05).Higher glucose level treated to H. pylori isolates enhance
the bacterial adhesion
With the treatment of 200 mg/dL of glucose to H. pylori
and AGS cells, the adhesion ability of strain J99 and
43504 was significantly enhanced as compared with that
of 150 and 100 mg/dL of glucose treatment (Figure 2A
and B). In order to test whether cellular factors play
some role in adhesion enhancement, strain J99 and 43504
growth in 100, 150, and 200 mg/dL of glucose adhered
to AGS cells with pretreatment of with contrary con-
centration (200, 150, 100 mg/dL), respectively (shown in
Figure 2C and D). Nevertheless, the adhesion abilities
within each strain were similarly disclosed with an in-
creasing trend based on the glucose level treated to thebacteria (strain J99 on Figure 2A and C; strain 43504 on
Figure 2B and D).
To check that the effect of glucose on increasing bac-
terial growth and adhesion not due to change osmolality,
we used L-glucose without biological activity to assess
the same experiment. Our data confirmed L-glucose did
not increase OD value at 72 h. Additionally, the adhesion
ability of both strains in either 150 or 200 mg/dL of glu-
cose were similar to that in 100 mg/dL (data not shown).Effect of glucose level on H. pylori type IV secretion
system-related virulence
BabA expression of H. pylori, in either strain J99 or 43504,
was similar among three glucose concentrations including
100, 150, and 200 mg/dL. However, for either one isolates,
the expression of CagA can be increased as the bacteria
exposed to glucose concentration which was raised from
100 to 200 mg/dL (Figure 3A). When H. pylori infected
to AGS cells, the cell-associated CagA of strain J99 pre-
sented with a significant stepwise increase by the glucose
treatment in level up to 150 and 200 mg/dL (p < 0.05),
as compared to the glucose treatment as 100 mg/dL
(Figure 3B). Also in Figure 3B, the cell-associated CagA
of strain 43504 had the similar scenario to that of strain
J99. Strain 43504 had a significantly increased trend of
phosphorylated CagA levels ranking in order parallel to
the elevation of glucose levels from 100, 150, and up to
200 mg/dL (p < 0.05, Figure 3B).
Figure 2 Adhesion ability of H. pylori increased under the treatment of higher glucose concentration. Strain J99 and 43504 growth in
different level of glucose (100, 150, 200 mg/dL) was added to AGS cells with the pretreatment of the same glucose concentration (A, B) or the
pretreatment of contrary concentration (200, 150, 100 mg/dL) (C, D). Relative adhesion ratio indicates that the adhesion of H. pylori in 100 mg/dL
of glucose serve as the reference, and the bacterial adhesion value in 150 and 200 mg/dL of glucose was divided by the value of reference.
*indicated a significant difference between the treatment of different glucose concentrations (paired t test, p < 0.05).
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The identification of cofactors involved in H. pylori-
related gastric carcinogenesis is important due to the
fact that not all H. pylori-infected patients developing
gastric cancer. Higher fasting plasma glucose levels in
H. pylori-seropositive patients significantly increased the
risk of gastric cancer, suggesting that hyperglycemia may
contribute to H. pylori-related gastric carcinogenesis [7,8].
The possible mechanisms by which hyperglycemia affects
H. pylori-related gastric carcinogenetic process include:
(1) glucose itself may activate Wnt/β-catenin pathway or
increase reactive oxygen species to induce DNA damage,
which contribute to H. pylori pathogenic effect; (2) hyper-
glycemia influences H. pylori and H. pylori-related infec-
tious status or stimulates its carcinogenic effect. However,
at present, the detailed mechanism is remains unclear.
In the present study, we demonstrate that higher glucose
could maintain H. pylori growth and viability after 48 h.
H. pylori adhesion and CagA expression was further
increased to facilitate the enhancement of cell-associated
CagA and phosphorylated CagA in higher glucoseconditions. These results support the second possible
mechanism.
Reynolds and Pann demonstrated that glucose enhances
H. pylori growth in a defined medium [28]. Albertson
et al. [29] found that the presence of glucose did not show
growth enhancement on H. pylori. This discrepancy may
be due to strain variations and detection methods utilized.
In the study of Albertson et al, growth and yield of H.
pylori (numbers of CFU per milliliter) was shown to
have no difference by adding 0.2 or 1.0% glucose (200
or 1000 mg/dL) to the defined medium supplemented
with 0.5% BSA. This could be due to the high bacterial
density (107 CFU/ml) at the beginning of inoculation.
Glucose was rapidly consumed and could not provide
for further growth because of growth and yield only
increased before 20 h. In our study, we found that higher
glucose concentrations (200 mg/dL) could keep up the
growth curve detected by OD at 600 nm after 48 h of
inoculation (Figure 1A and B). Moreover, the viability
of H. pylori at the same concentration of glucose was
obviously higher than that of 100 or 150 mg/dL at 72 h
Figure 3 Figure 3 H. pylori CagA and phosphorylated CagA
increased in higher glucose concentration. (A) BabA and CagA
expression of H. pylori grown in three glucose concentrations.
(B) The level of cell-associated CagA and phosphorylated CagA after
H. pylori infecting AGS cells for 4 h. Thee glucose concentrations
were 100, 150 and 200 mg/dL, respectively. *indicated a significant
difference between the treatment of different glucose concentrations
(paired t test, p < 0.05).
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et al. [29]. They found that viability of H. pylori in the pres-
ence of glucose obviously retains after inoculation of 2 days,
as compared to non-glucose addition. We further provide
the result that glucose can enhance H. pylori viability
with a dose-dependent effect at 72 h (Figure 1C and D).
Whether or not an infection rate of H. pylori is higher in
DM patients remains controversial. Some studies report
that the prevalence of H. pylori in DM patients shows no
significant difference as compared to controls [30,31]. In
these articles, only the H. pylori infection rate was studied,
but no more detailed analysis was conducted to trace the
H. pylori density-related histology or virulence severity. Our
study revealed that H. pylori adhesion was enhanced inhigher glucose concentrations (Figure 2A and B). We pro-
vide data supporting the possibility that glucose may influ-
ence H. pylori density colonizing on the gastric epithelium.
H. pylori colonization could further interact with gastric
epithelium to induce gastric inflammation [32,33]. In dia-
betic patients, H. pylori infection was significantly associated
with chronic gastritis, but not in dyspeptic patients [34].
This study should be considered as being original to
illustrate that bacterial adhesion to gastric epithelial cells
can be enhanced by a higher glucose condition. H. pylori
growth in 100, 150 and 200 mg/dL of glucose is shown
to have an increasing trend after being added to AGS
cells pretreated with contrary concentrations of glucose
(Figure 2C and D). It indicates that bacterial factors
may play a more important role in increasing adhesion.
When we analyzed BabA expression of H. pylori growth
in three different glucose conditions, it did not show
significant differences (Figure 3A). However, CagA expres-
sion was elevated as H. pylori growth in the increasing
concentration of glucose (Figure 3A). Cell-associated
CagA of strain J99 and phosphorylated CagA of strain
43504 were significantly increased in higher glucose
conditions of infection (150 and 200 mg/dL) (Figure 3B).
Therefore, the enhancement of cell-associated or phos-
phorylated CagA could be due to the elevated adhesion
ability and CagA expression of H. pylori in higher glucose
conditions (Figures 2A, B and 3A).
Ishijima et al. [33] demonstrated that BabA-mediated
adherence increases the effectiveness of H. pylori type IV
secretion activity, implying the promoting role of H. pylori
adhesion in type IV secretion activity. Moreover, phosphor-
ylation of CagA is essential for induction of gastrointestinal
neoplasm in transgenic mice [35]. Due to the elevated
phosphorylated CagA in higher glucose conditions, it
may further contribute to facilitate a more evident gastric
carcinogenesis in the H. pylori-infected DM patients.
Conclusions
In summary, we provide in vitro evidence that H. pylori
growth, viability, CagA and phosphorelated CagA after
infecting gastric epithelial cells could be enhanced in
higher glucose condition, supporting that hyperglycemia
could be a cofactor to increase a risk of H. pylori related
gastric carcinogenesis. The evidence would indicate that it
is important to conduct large-scale H. pylori screening and
eradication to control the increased risk of gastric cancer
for DM patients, especially in high H. pylori-infected or
gastric cancer prevalent countries.
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